16 December 2015 - The advanced breast cancer treatment trastuzumab emtansine (marketed by Roche as Kadcyla) will not be available through normal funding routes on the NHS in England, final guidance from the UK National Institute for Health and Care Excellence has said.

For more details, go to: http://www.bmj.com/content/351/bmj.h6837?etoc=